When you're locked in a biotech licensing dispute, the stakes are pretty clear: control of promising therapies and potentially millions in milestone payments. Tuesday brought a decisive outcome in one such battle, and Cellectis S.A. (CLLS) shareholders weren't happy about it.

Allogene Therapeutics Inc. (ALLO) announced that its partner Servier scored a major arbitration win against Cellectis over their CAR-T therapy cemacabtagene ansegedleucel, mercifully shortened to cema-cel. The ruling reconfirmed Allogene's full development and commercial control of cema-cel across the U.S., EU, and U.K., while clearing the runway for the company to eventually secure global commercialization rights from Servier.

What the Tribunal Actually Said

The arbitration panel didn't just side with Servier on a technicality. It systematically dismantled Cellectis's case on multiple fronts.

First, the tribunal rejected Cellectis's allegations that Servier breached its development obligations. Strike one.

Second, and perhaps most financially significant, it tossed out Cellectis's claims for milestone payments. The panel ruled these payments tied to pivotal trials aren't actually due until the U.S. Food and Drug Administration accepts a Biologics License Application. In other words: no FDA filing acceptance, no payment.

Third, the tribunal ordered only a partial license termination, limited strictly to the UCART19 V1 product, formerly known as ALLO-501. Here's the thing though: Allogene discontinued that version back in 2021 in favor of ALLO-501A, which is the current cema-cel product. So this termination applies to something already shelved. The tribunal also directed Cellectis to negotiate a direct license to Allogene on substantially similar terms to the existing agreement, if Allogene decides it wants one.

Why This Matters Now

With this legal overhang resolved, Allogene enters 2026 with cleaner fundamentals and better visibility. The timing matters because the company is heading into what could be one of the most significant catalyst periods in the allogeneic CAR-T field.

In the first half of 2026, Allogene expects an interim futility analysis comparing minimal residual disease conversion with cema-cel following standard fludarabine/cyclophosphamide lymphodepletion versus observation in first-line patients with large B-cell lymphoma.

Price Action: CLLS stock dropped 17.35% to $3.96, while ALLO stock gained 1.37% to $1.49 on Tuesday.